

Alector to Host Mid-Year Earnings Conference Call

July 31, 2024

Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call.

The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations https://investor.com/events-and-presentations https://investor.com/events-and-presentations <a hre

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector's immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer's disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alector Contacts:

Alector Katie Hogan 202-549-0557 katie.hogan@alector.com

1AB (media) Dan Budwick 973-271-6085 dan@1abmedia.com

Argot Partners (investors) Laura Perry 212.600.1902 alector@argotpartners.com



Source: Alector, Inc.